Drug Approval | January 05, 2026
FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The complex four-hour surgery was performed by a multidisciplinary team of doctors
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Subscribe To Our Newsletter & Stay Updated
